Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Daresbury Proteins is a UK-based biotechnology company specializing in the production of high-quality, difficult-to-express recombinant human proteins using its proprietary mammalian expression platform. The company's technology enables rapid generation of stable cell pools and high-yield production of authentic proteins with correct post-translational modifications, primarily for research, diagnostic, and clinical applications. Daresbury Proteins offers a catalog of proteins including FGFR, VAP-1, and APP, while also providing custom cell line development and protein manufacturing services to pharmaceutical and academic partners. Their platform is designed to reduce the cost and time associated with clonal cell line development, supporting the rapid assessment of therapeutic candidates. The company has established key partnerships with organizations like Thermo Fisher Scientific and Iksuda Therapeutics to advance biomanufacturing and drug discovery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Daresbury Proteins.